A fixed-dose combination (FDC) of two nootropic agents with complementary mechanisms targeting cerebral metabolism and neuroprotection. Citicoline (Cytidine-5'-diphosphocholine) is an endogenous nucleotide that serves as an intermediate in the synthesis of phosphatidylcholine, a key neuronal membrane phospholipid. Piracetam is a cyclic derivative of GABA (2-oxo-1-pyrrolidine acetamide) and is the prototypical racetam nootropic. This combination is primarily used in the Indian market for cognitive enhancement and recovery in various cerebrovascular and neurodegenerative conditions. The combination aims to synergistically improve neuronal membrane integrity, enhance cerebral metabolism, and modulate neurotransmission.
Adult: One tablet (Citicoline 500mg + Piracetam 400mg) twice daily, preferably with meals. May be increased to one tablet three times daily based on clinical response and tolerability.
Note: Administer orally with a full glass of water, preferably with food to minimize potential gastrointestinal upset. Tablets should be swallowed whole, not chewed or crushed. Maintain adequate hydration.
The combination works via complementary pathways to enhance brain function. Citicoline provides the rate-limiting substrates (cytidine and choline) for the Kennedy pathway, leading to increased synthesis of phosphatidylcholine, a critical component of neuronal membranes. This aids in membrane repair and integrity. It also increases acetylcholine synthesis, dopamine receptor density, and reduces free fatty acid accumulation post-ischemia. Piracetam modulates neuronal and vascular functions, potentially by restoring cell membrane fluidity, facilitating interhemispheric communication via the corpus callosum, and enhancing neuroplasticity. It may also have antiplatelet and rheological effects, improving microcirculation.
Pregnancy: Category B (US FDA classification for piracetam; citicoline data insufficient). Animal studies show no risk, but human data lacking. Use only if potential benefit justifies potential risk to the fetus. Not recommended during pregnancy.
Driving: May cause dizziness, drowsiness, or visual disturbances in some patients. Patients should not drive or operate machinery until their individual response is known.
| Anticoagulants (Warfarin, Acenocoumarol) & Antiplatelets (Clopidogrel, Aspirin) | Piracetam may inhibit platelet aggregation, increasing the risk of bleeding. Monitor INR and for signs of bleeding. | Major |
| Antihypertensives | Piracetam may cause a slight increase in blood pressure, potentially counteracting the effect. Monitor BP. | Moderate |
| Levodopa | Citicoline may potentiate the effects of levodopa, potentially increasing dyskinesias or therapeutic effects. Dose adjustment may be needed. | Moderate |
| Central Nervous System Depressants (Alcohol, Benzodiazepines, Barbiturates) | Additive sedative effects may occur, though piracetam is often stimulatory. Use with caution. | Moderate |
| Thyroid Hormone (Levothyroxine) | Citicoline may increase T4 absorption; monitor thyroid function if started or stopped. | Minor |
Same composition (Citicoline (500mg) + Piracetam (400mg)), different brands: